Eccogene
ECC4703
Adult Obesity
Countdown
101days
Phase 2 readout · Oct 15, 2026
What's at stake
Phase 2 trial results for ECC4703 in Adult Obesity are due Oct 15, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07505303: Phase 2 trial, sponsor Eccogene, drug ECC4703. Primary completion date 2026-10-15 (estimated).”